Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VG161 in Advanced Primary Liver Cancer
NCT04806464Phase 1Recruiting
- Sponsor
- Virogin Biotech
- Start
- Mar 2021
- Primary completion
- Mar 2022
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VG161 in hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and Combined hepatocellular-cholangiocarcinoma (cHCC-CC), sponsored by Virogin Biotech. Primary endpoints: Maximum Tolerated Dose / Recommended Dose at 7 months, Occurrence of Dose Limiting Toxicity at 1 month and 4 more. Started Mar 2021; status: recruiting.
02
Drugs
VG161
03
Conditions
hepatocellular carcinoma (HCC)intrahepatic cholangiocarcinoma (ICC)Combined hepatocellular-cholangiocarcinoma (cHCC-CC)
Beyond the preview
Go deeper on NCT04806464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04806464.